Barclays analyst Matt Miksic lowered the firm’s price target on Boston Scientific (BSX) to $100 from $124 and keeps an Overweight rating on the shares. The firm reduced estimates and the stock’s target multiple to reflect management’s comments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX: